# KEYNOTE-087 (NCT02453594)

> Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: relapsed or refractory classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02453594
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hodgkin Lymphoma
- Interventions: pembrolizumab
- Enrollment: 211
- Primary outcome: Overall Response Rate (ORR) by BICR Based on IWG Criteria
- Primary outcome: Percentage of Participants Experiencing at Least One Adverse Event (AE)
- Primary outcome: Percentage of Participants Discontinuing Study Drug Due to AEs

## Indexed commentary on KEYNOTE-087 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-087-nct02453594

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02453594", "email": "<work email>"}; the inbox owner confirms by the emailed link.